Your browser is no longer supported. Please, upgrade your browser.
Settings
RAPT RAPT Therapeutics, Inc. daily Stock Chart
RAPT [NASD]
RAPT Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own1.10% Shs Outstand24.23M Perf Week0.87%
Market Cap733.44M Forward P/E- EPS next Y-2.99 Insider Trans0.00% Shs Float23.64M Perf Month-17.63%
Income-39.20M PEG- EPS next Q-0.70 Inst Own64.90% Short Float0.96% Perf Quarter48.53%
Sales- P/S- EPS this Y-24.20% Inst Trans19.61% Short Ratio2.32 Perf Half Y-
Book/sh-133.47 P/B- EPS next Y-31.70% ROA- Target Price38.50 Perf Year-
Cash/sh1.99 P/C15.19 EPS next 5Y- ROE- 52W Range11.85 - 51.21 Perf YTD9.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.89% Beta-
Dividend %- Quick Ratio9.40 Sales past 5Y- Gross Margin- 52W Low155.44% ATR3.98
Employees64 Current Ratio9.40 Sales Q/Q- Oper. Margin- RSI (14)41.19 Volatility6.65% 11.89%
OptionableNo Debt/Eq- EPS Q/Q3.00% Profit Margin- Rel Volume0.68 Prev Close30.14
ShortableYes LT Debt/Eq- EarningsMar 11 Payout- Avg Volume98.07K Price30.27
Recom2.00 SMA20-24.73% SMA50-6.73% SMA2005.18% Volume66,320 Change0.43%
Nov-25-19Initiated Wells Fargo Outperform $33
Nov-25-19Initiated UBS Buy $26
Nov-25-19Initiated BMO Capital Markets Outperform $35
Feb-07-20 06:45AM  RAPT Therapeutics Announces Pricing of $75 Million Public Offering GlobeNewswire -10.71%
Feb-04-20 05:43PM  RAPT Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
Jan-31-20 11:27AM  We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth Simply Wall St.
Jan-07-20 08:00AM  RAPT Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-16-19 08:00AM  RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices GlobeNewswire
Dec-11-19 08:00AM  RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights GlobeNewswire -7.44%
Dec-10-19 08:00AM  RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors GlobeNewswire
Dec-04-19 08:00AM  RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer GlobeNewswire +10.34%
07:06AM  The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Benzinga
Dec-03-19 04:05PM  RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia GlobeNewswire +14.82%
03:29PM  Biotech IPO Frenzy Brings in 3 Stocks to Buy TipRanks
Nov-11-19 10:56AM  Weekly CEO Buys Highlight GuruFocus.com -30.25%
Oct-30-19 08:49PM  RAPT Therapeutics Announces Pricing of Initial Public Offering Business Wire
Jul-30-19 03:25PM  Rapt Therapeutics IPO: What You Need To Know Benzinga
Jul-28-19 02:08PM  IPO Outlook For The Week: Cannabis, Cancer Therapy, Sushi And Holographic AR Benzinga
RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.